1. Introduction {#sec1}
===============

Species in the *C. albicans* complex can colonize in the vaginal tract. Through changes in the relationship between the host and this commensal yeast, an invasive form may occur ([@bib11]) causing mucosal infection and vulvovaginal candidiasis (VVC) ([@bib12]). In 2001, *C. albicans* isolates of African and German patients with atypical phenotypes were described as a novel species, *C. africana* ([@bib31]). *C. africana* produces a germ tube but not chlamydospores. *C. albicans* remains the most common pathogenic yeast isolated from vaginal specimens of VVC patients, but the closely-related *C. africana* and *C. dubliniensis* have often been mistaken for *C. albicans*. *C. africana* has been isolated from candidal balanoposthitis in China ([@bib13]), and clinical isolates have been reported as the cause of VVC in Germany, China, Italy, Iran, Nigeria, Spain, the United Kingdom, Argentina, Colombia, among other countries ([@bib31]; [@bib3]; [@bib25]; [@bib8]; [@bib20]; [@bib4]; [@bib28]; [@bib23]; [@bib32]; [@bib30]). The vaginal candidiasis studies in Iran have been identified susceptible ([@bib32]) and resistant ([@bib16]) antifungal drugs *C. africana* isolates.

Molecular methods are suitable for identification of *Candida* species. The use of the ribosomal DNA (rDNA) ITS region for sequence-analysis appears to be the most sensitive and specific method for accurate and reliable molecular identification of *Candida* species ([@bib17]; [@bib33]). The sequencing of a short fragment of the ITS2 region has been shown effective in detecting the presence of *C. africana* in clinical *Candida* infections ([@bib4]). Duplex PCR is a suitable method for identification of isolates such as *C. albicans* and *C. dubliniensis* ([@bib1]). Amplification of the *HWP1* gene was the first molecular method for discriminating *C. albicans*, *C. dubliniensis*, and *C. africana* ([@bib24]). Many antifungal agents are effective treating VVC, but some vaginal *Candida* isolates have developed resistance to antifungal drugs. Assessment of antifungal susceptibility of pathogenic yeasts is essential to proper therapy and will allow evaluation of their efficacy and treatment results as well as prevention of drug resistance ([@bib18]; [@bib9]). However, there is limited information about the prevalence and antifungal susceptibility of *C. africana* in VVC in Iran. The aim of this study was to identify *C. africana* and *C. dubliniensis* in vaginal samples from VVC patients and to evaluate their antifungal susceptibility pattern.

2. Materials and methods {#sec2}
========================

2.1. Patients, sample collection and definitions {#sec2.1}
------------------------------------------------

The present study analyzed clinical isolates of vaginal discharge from 300 non-pregnant patients aged 18--57 years with suspected VVC admitted to the Shahid Akbar Abadi hospital and Shahriar health centers from June through December 2016, along with culture samples from our laboratory. Patients had not used antifungal drugs within the preceding four weeks. Samples were collected with sterile cotton swabs, and microscopic examination was done to identify yeast forms or pseudohyphae. In addition, 30 *Candida* spp. of the *C. albicans* complex obtained from VVC patients were selected from the culture collection of the medical mycology laboratory in our department. All specimens were cultured on CHROMagar *Candida* medium (CHROMagar, France) at 37 °C for 24--48 hrs for detection of mixed *Candida* spp. infections. A single colony of each *Candida* isolate on CHROMagar *Candida* medium was selected and cultured on Sabouraud dextrose agar (SDA) medium with chloramphenicol at 30 °C for 48--72 hrs for further use. The germ tube test, chlamydospore-forming assay on corn meal agar (CMA) with 1% Tween 80 and growth on SDA medium with chloramphenicol at 42 °C and 45 °C was conducted.

2.2. DNA extraction {#sec2.2}
-------------------

A single colony of each clinical isolate from CHROMagar *Candida* medium was cultured on yeast extract peptone dextrose (YEPD) agar and incubated at 37 °C for 24--48 hrs. Genomic DNA was extracted from yeast cultures using the Qiagen DNA tissue kit (Germany). The extracted DNA was stored at -20 °C until use.

2.3. PCR amplification and sequencing of ITS region {#sec2.3}
---------------------------------------------------

The universal primers ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 (5′-TCCTCC GCTTATTGATATGC-3′) were used to amplify the ITS1-5.8S-ITS2 region ([@bib10]; [@bib5]) under the following conditions: 98 °C at 5 min; 35 cycles of 30 s at 98 °C, annealing for 30 s at 56 °C, 30 s at 72 °C, and a final extension of 5 min at 72 °C. The PCR products were sequenced by Macrogen (Korea). Sequences were compared with reference data available from the GenBank database using the BLAST sequence search tool (<http://www.ncbi.nlm.nih.gov/BLAST>).

2.4. Duplex PCR {#sec2.4}
---------------

*C. albicans* and *C. dubliniensis* strains were analyzed by duplex PCR with paired primers CALF (5′-TGGTAAGGCGGGATCGCTT-3′) and CALR (5′-GGTCAAAGTTTGAAGATATAC-3′) for *C. albicans* and CDUF (5′-AAACTTGTCACGAGATTATTTTT-3′) and CDUR (5′-AAAGTTTGAAGAATAAAATGGC-3′) for *C. dubliniensis* ([@bib1]). Specific primers used the following PCR protocol: 95 °C for 5 min; 30 cycles of 1 min at 95 °C, 30 s at annealing temperature 55 °C, and 1 min at 72 °C; and a final extension of 10 min at 72 °C.

2.5. PCR amplification of *HWP1* gene {#sec2.5}
-------------------------------------

The PCR primers (CR-f 5′-GCTACCACTTCAGAATCATCATC-3′ and CR-r 5′-GCACCTTCAGTCGTAGAGACG-3′) used to amplify the *HWP1* gene for detection *C. albicans, C. africana* and *C. dubliniensis*, as previously described by [@bib24].

Reference strains used as control were *C. albicans* (ATCC10231) and *C. dubliniensis* from the archives of department of Medical Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences. *C. dubliniensis* was 100% confirmed by sequencing to species level.

2.6. In vitro antifungal susceptibility testing {#sec2.6}
-----------------------------------------------

The *in vitro* susceptibility was determined by the Clinical and Laboratory Standards Institute (CLSI) (CLSI M27-S3 [@bib6]; CLSI M27-S4 [@bib7]). Briefly, final inocula of 0.5×10^3^ to 2.5×10^3^ colony-forming units/ml were distributed in 96 well microtiter plates in RPMI 1640 medium buffered to pH 7.0 with 0.165M morpholinepropanesulfonic acid with diluted antifungal drugs and incubated at 35 °C. The antifungals used were amphotericin B, itraconazole, fluconazole, and clotrimazole (Sigma, Germany), and all tests were duplicated. *C. glabrata* CBS 138 was used as quality control strain. According to CLSI M27-S3 criteria for fluconazole, the sensitivity profile is classified as sensitive (≤8 μg/ml), dose-dependent sensitive (16--32 μg/ml), and resistant (≥64 μg/ml), and breakpoints for itraconazole is sensitive (≤0.125 μg/ml), dose-dependent sensitive (0.25--0.5 μg/ml), and resistant (≥1 μg/ml).

2.7. Ethical approval {#sec2.7}
---------------------

This research was approved by Ethics Committee of Iran University of Medical Sciences, under Ethics Committee number 95-01-30-27842.

2.8. Informed consent {#sec2.8}
---------------------

Written informed consent was obtained from all patients.

3. Results {#sec3}
==========

3.1. Patients {#sec3.1}
-------------

All patients diagnosed with VVC (23%) were in the 18--50 years age range. None exhibited diabetes, immunodeficiency, or other chronic disease. The archival information on VVC patients indicated a very similar age range, 18--50 years, and without disease.

3.2. Yeast isolates {#sec3.2}
-------------------

One hundred isolates belonging to the *C. albicans* complex were identified, 97 as *C. albicans* (data not shown) 97% and three (3%) as *C*. *africana. C. africana* produced small turquoise-green colonies on CHROMagar *Candida* and did not produce chlamydospores on CMA medium. *C. albicans* isolates proliferated at 42 °C and 45 °C, while the *C. africana* isolates did not.

3.3. Duplex PCR assay {#sec3.3}
---------------------

The results of amplification of isolates with CALF/CALR and CDUF/CDUR specific primers for *C. albicans* and *C. dubliniensis*, respectively, for duplex PCR assay, were determined for a \~100 bp fragment of *C. albicans* and a \~325 bp fragment of *C. dubliniensis* ([Figure 1](#fig1){ref-type="fig"}). No *C. dubliniensis* isolates were found in this study.Figure 1Agarose gel of duplex PCR using primers CALF, CALR, CDUF andCDUR. Lane 1: *C. albicans* clinical isolate (\~100 bp); Lane 2: positive control *C. dubliniensis* (\~325 bp) from the archives of the Department of Medical Parasitology and Mycology; Lane 3: positive controls *C. albicans* (ATCC10231) and *C. dubliniensis*. N: negative control. M: marker 100 bp.Figure 1

3.4. PCR amplification and sequencing of ITS region {#sec3.4}
---------------------------------------------------

Amplification of all clinical isolates of *C. albicans* complex with ITS1 and ITS4 primers yielded fragments of 530 bp for both *C. albicans* and *C. africana* ([Figure 2](#fig2){ref-type="fig"}). The ITS region sequences of *Candida* spp. clinical isolates were compared in the GenBank database using BLAST. All clinical isolates showed 100% and 99% similarity to *C. albicans* or *C. africana*. The ITS sequences of *C*. *africana* isolates were deposited in GenBank under accession numbers MG757669, MG757670, and MG757671.Figure 2Clinical isolates of *C. albicans* complex analyzed with ITS1 and ITS4 universal primers; 530 bp fragment produced. Lanes 1--8: *C. albicans*; Lanes 9--11: *C*. *africana*; N: negative control. M: marker 50 bp.Figure 2

3.5. PCR amplification with specific primers of *HWP1* gene {#sec3.5}
-----------------------------------------------------------

The results of partial amplification of isolates with specific primers of *HWP1* gene yielded fragments of \~900 bp, \~700 bp and \~560 bp for *C. albicans*, *C*. *africana* and *C. dubliniensis*, respectively ([Figure 3](#fig3){ref-type="fig"}).Figure 3Agarose gel of PCR amplification with specific primers of *HWP1* gene; Lane 1: *C. albicans* (ATCC10231) \~900 bp; Lanes 2--4: *C. africana* (\~700 bp); Lane 5: positive control of *C. dubliniensis* (\~560 bp) from the archives of the Department of Medical Parasitology and Mycology; N: negative control. M: marker 100 bp.Figure 3

3.6. Antifungal susceptibility testing {#sec3.6}
--------------------------------------

*Candida africana* isolates were classified as sensitive, dose-dependent sensitive, or resistant to antifungal agents based on their minimum inhibitory concentration (MIC) according to the M27-S3 protocol ([Table 1](#tbl1){ref-type="table"}). One isolate of *C. africana* isolates showed resistance to both clotrimazole (MIC ≥ 1 μg/ml) ([@bib22]) and fluconazole (MIC ≥ 64 μg/ml). One isolate showed susceptibity in a dose-dependent manner to itraconazole (0.25--0.5 μg/ml). Clinical *C. africana* isolates were susceptible to amphotericin B.Table 1*In vitro* susceptibility profile of three *C. africana* vaginal isolates using the breakpoints of CLSI M27- S3[a](#tbl1fna){ref-type="table-fn"}.Table 1IsolatesAntifungal agentsDosage Range\
μg/mlNumber of isolatesS[b](#tbl1fnb){ref-type="table-fn"}S-DD[c](#tbl1fnc){ref-type="table-fn"}R[d](#tbl1fnd){ref-type="table-fn"}*C. africana*Fluconazole0.25--642-1Clotrimazole0.06--162-1Itraconazole0.06--1621-Amphotericin B0.06--2.03\--[^1][^2][^3][^4]

4. Discussion {#sec4}
=============

The female genital tract is a common site of pathogenic growth of *Candida* spp., and VVC is a common infection. *C. albicans* is reported to be the most common yeast species involved in VVC ([@bib2]; [@bib15]; [@bib14]). Species of *C. albicans* complex include *C. albicans*, *C. dubliniensis*, *C. africana* and *C. stellatoidea* that are important in vaginitis, with *C. albicans* the primary agent of *Candida* infections. *C. dubliniensis* was identified as the most common cause of oral candidiasis in HIV-infected individuals ([@bib29]). Accurate identification of these closely related yeasts is facilitated by the use of both conventional and molecular methods. *C. africana* (6%) has been reported to be more prevalent than *C. dubliniensis* ([@bib4]), with worldwide distribution identified from vaginal discharge, candidal balanoposthitis, and blood culture ([@bib21]; [@bib26]; [@bib27]; [@bib13]). The present study confirmed *C. africana* (3%), in the *C*. *albicans* complex, as an important agent of VVC. In order to administer effective treatment, the species must be identified, since some show resistance to antifungal drugs. The *HWP1* gene amplification is adequate to identify species of this complex ([@bib13]), and sequencing of the ITS region has proven to be a feasible method for the reliable identification of clinically important yeasts. *C. dubliniensis* and *C. stellatoidea* were not detected in our study. Other studies of VVC have also not reported *C. dubliniensis* isolate ([@bib20]; [@bib28]; [@bib13]; [@bib19]) while some have found it to have higher prevalence than *C. africana* ([@bib4]; [@bib30]). Romeo et al. ([@bib25]) studied isolates of *C. albicans* (338)*, C. africana* (27), *and C. dubliniensis* (11) from several anatomical sites and found *C. albicans* (89.9%) to be the most common species, followed by *C. africana* (7.2%) and *C. dubliniensis* (2.9%), with *C. africana* isolated only from vaginal secretions. An investigation from China ([@bib13]) found five *C. africana* isolates (6.3%) involved in candidal balanoposthitis to be susceptible to fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, flucytosine, micafungin, and amphotericin B. [@bib28] reported that *C. africana* isolates (1.5%) from vaginal specimens from China were susceptible to nystatin, fluconazole, itraconazole, miconazole, and clotrimazole, while another study reported five (4.38 %) *C*. *africana* VVC isolates to be susceptible to tested antifungal agents ([@bib32]). [@bib30] showed low MIC values of nystatin, fluconazole, itraconazole, voriconazole, clotrimazole, and terbinafine to *C*. *africana* and *C. dubliniensis* vaginal isolates. [@bib4] showed *C. africana* isolates to be susceptible to tested antifungal agents suitable for VVC treatment. [@bib19] reported a *C*. *africana* isolate in vaginal samples from HIV infected patients to be resistant to ketoconazole and exhibit reduced susceptibility to amphotericin B. Majdabadi et al., isolated two *C. africana* of vaginal candidiasis in which one species was resistant to fluconazole and itraconazole, the other one to itraconazole ([@bib16]). We found one *C. africana* vaginal isolate resistant to both clotrimazole and fluconazole, and another one showed dose-dependent susceptibility to itraconazole.

5. Conclusion {#sec5}
=============

Our finding of *C. africana* as a rare agent of vaginitis resistant to both clotrimazole and fluconazole with reduced susceptibility to itraconazole is important in VVC treatment. Identification of *C. africana* as an uncommon agent of VVC is critical, since this yeast showed a range of susceptibility to antifungal agents.
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[^1]: CLSI document M27- S3 (2008).

[^2]: S: sensitive.

[^3]: S-DD: susceptible dose-dependent.

[^4]: R: resistant.
